NEW YORK – Zai Lab and Turning Point said on Monday that Zai has obtained exclusive rights to TPX-0022, Turning Point’s MET, SRC, and CSF1R inhibitor, in Greater China.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.